Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Semaglutide52 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00305 | 35143711 | Clin Transl Sci | Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | 2021 | Details |
| A01894 | 34570916 | Aliment Pharmacol Ther | Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. | 2021 | Details |
| A02194 | 34465857 | Int J Obes (Lond) | Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist. | 2021 | Details |
| A02287 | 34435378 | Aliment Pharmacol Ther | Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. | 2021 | Details |
| A02349 | 34406410 | J Clin Endocrinol Metab | The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. | 2022 | Details |
| A03013 | 34164242 | Cureus | Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. | 2021 | Details |
| A04749 | 33515800 | Ann Hepatol | Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. | 2021 | Details |
| A04758 | 33513761 | Metabolites | Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. | 2021 | Details |
| A04924 | 33447122 | Clin Med Insights Endocrinol Diabetes | Oral GLP1 Analog: Where Does the Tide Go? | 2020 | Details |
| A05624 | 33185364 | N Engl J Med | A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. | 2020 | Details |
| A06005 | 33039693 | Contemp Clin Trials | Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. | 2020 | Details |
| A06147 | 32987188 | Mol Metab | Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. | 2020 | Details |
| A08113 | 32243137 | Bioconjug Chem | New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice. | 2020 | Details |
| A08128 | 32237916 | Expert Opin Pharmacother | Current and new pharmacotherapy options for non-alcoholic steatohepatitis. | 2020 | Details |
| A10476 | 31321014 | Ther Adv Chronic Dis | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. | 2019 | Details |
| A10662 | 31246368 | Aliment Pharmacol Ther | Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. | 2019 | Details |
| A11125 | 31031702 | Front Endocrinol (Lausanne) | The Discovery and Development of Liraglutide and Semaglutide. | 2019 | Details |
| A14182 | 29547706 | Atherosclerosis | Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. | 2018 | Details |
| A14539 | 29363040 | Drugs | Semaglutide: First Global Approval. | 2018 | Details |
| A29068 | 34626851 | Mol Metab | GLP-1 physiology informs the pharmacotherapy of obesity. | 2021 | Details |
| A29923 | 33268008 | Bioorg Chem | Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent. | 2020 | Details |
| A42530 | 34233105 | N Engl J Med | Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply. | 2021 | Details |
| A42531 | 34233104 | N Engl J Med | Semaglutide or Placebo for Nonalcoholic Steatohepatitis. | 2021 | Details |
| A42632 | 33960005 | Hepatology | The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis. | 2021 | Details |
| A42864 | 33257834 | Nat Rev Gastroenterol Hepatol | Semaglutide is safe and efficacious for NASH resolution. | 2021 | Details |
| A44116 | 29702499 | Curr Opin Cardiol | New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. | 2018 | Details |
| A44508 | 28434491 | Lancet Diabetes Endocrinol | Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply. | 2017 | Details |
| A44509 | 28434490 | Lancet Diabetes Endocrinol | Semaglutide, lipid-lowering drugs, and NAFLD. | 2017 | Details |
| A47642 | 34430539 | Hepatobiliary Surg Nutr | Semaglutide for nonalcoholic steatohepatitis: closer to a solution? | 2021 | Details |
| A47643 | 34430533 | Hepatobiliary Surg Nutr | Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. | 2021 | Details |
| A47896 | 29870275 | Diabetes Technol Ther | The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. | 2018 | Details |
| A47935 | 28847797 | Circulation | Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. | 2017 | Details |
| A48549 | 34267725 | Front Endocrinol (Lausanne) | Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. | 2021 | Details |
| A49208 | 35822119 | JGH Open | Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. | 2022 | Details |
| A49279 | 35803320 | Metabolism | Recent guidelines for non-alcoholic fatty liver disease (NAFLD): Are they already outdated and in need of supplementation? | 2022 | Details |
| A49515 | 35728962 | Cas Lek Cesk | An overview of current therapy options of non-alcoholic fatty liver disease. | 2022 | Details |
| A49574 | 35709586 | Diabetes Metab Syndr | Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis. | 2022 | Details |
| A49608 | 35693370 | Cureus | Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review. | 2022 | Details |
| A49748 | 35650449 | Pharm Res | Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. | 2022 | Details |
| A49865 | 35614896 | Visc Med | Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review. | 2021 | Details |
| A49933 | 35589613 | Diabetes Obes Metab | Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. | 2022 | Details |
| A50153 | 35501557 | Curr Obes Rep | Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50241 | 35461369 | Sci Rep | Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. | 2022 | Details |
| A50298 | 35439567 | J Hepatol | Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. | 2022 | Details |
| A50654 | 35312970 | Diabetes Ther | Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study. | 2022 | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | 2022 | Details |
| A50788 | 35266164 | Aliment Pharmacol Ther | Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. | 2022 | Details |
| A51118 | 35668318 | Hormones (Athens) | Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer. | 2022 | Details |
| A51161 | 35427802 | Clin Res Hepatol Gastroenterol | The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice. | 2022 | Details |
| A51388 | 30623143 | JACC Basic Transl Sci | The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. | 2018 | Details |